The Role of 18F-FDG PET/CT in Staging and Prognostication of Mantle Cell Lymphoma: An Italian Multicentric Study.

18F-FDG PET/CT Deauville criteria mantle cell lymphoma prognosis

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
21 11 2019
Historique:
received: 06 10 2019
revised: 13 11 2019
accepted: 19 11 2019
entrez: 27 11 2019
pubmed: 27 11 2019
medline: 27 11 2019
Statut: epublish

Résumé

Mantle cell lymphoma (MCL) is an aggressive lymphoma subtype with poor prognosis in which 18F-FDG-PET/CT role in treatment response evaluation and prediction of outcome is still unclear. The aim of this multicentric study was to investigate the role of 18F-FDG-PET/CT in staging MCL and the prognostic role of Deauville criteria (DC) in terms of progression-free survival (PFS) and overall survival (OS). We retrospectively enrolled 229 patients who underwent baseline and end-of-treatment (eot) 18F-FDG-PET/CT after first-line therapy. EotPET/CT scans were visually interpreted according to DC. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of PET/CT for evaluation of bone marrow (BM) were 27%, 100%, 100%, 48% and 57%, respectively. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of PET/CT for evaluation of the gastrointestinal (GI) tract were 60%, 99%, 93%, 90% and 91%, respectively. At a median follow-up of 40 months, relapse occurred in 104 cases and death in 49. EotPET/CT results using DC significantly correlated with PFS, not with OS. Instead, considering OS, only MIPI score was significantly correlated. In conclusion, we demonstrated that MCL is an FDG-avid lymphoma and 18F-FDG-PET/CT is a useful tool for staging purpose, showing good specificity for BM and GI evaluation, but suboptimal sensitivity. EotPET/CT result was the only independent significant prognostic factor that correlated with PFS.

Identifiants

pubmed: 31769415
pii: cancers11121831
doi: 10.3390/cancers11121831
pmc: PMC6966583
pii:
doi:

Types de publication

Journal Article

Langues

eng

Déclaration de conflit d'intérêts

The authors declare they have no conflict of interest.

Références

Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):731-736
pubmed: 30075973
Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1837-48
pubmed: 27154522
Hematol Oncol. 2018 Feb;36(1):110-115
pubmed: 29083050
Blood. 2008 Jan 15;111(2):558-65
pubmed: 17962512
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Clin Nucl Med. 2011 Jun;36(6):452-6
pubmed: 21552023
Ann Oncol. 2014 May;25(5):921-7
pubmed: 24351400
Clin Lymphoma Myeloma Leuk. 2011 Jun;11(3):261-6
pubmed: 21658653
Front Med (Lausanne). 2019 Apr 09;6:70
pubmed: 31024918
Leuk Lymphoma. 2014 Nov;55(11):2484-9
pubmed: 24432895
Ann Hematol. 2015 Dec;94(12):2025-32
pubmed: 26411584
Nucl Med Commun. 2009 Oct;30(10):770-8
pubmed: 19657307
Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):e266-e272
pubmed: 31000497
Leuk Lymphoma. 2010 Dec;51(12):2171-80
pubmed: 21077737
Ann Nucl Med. 2019 Jul;33(7):449-458
pubmed: 30929200
Blood. 2018 Oct 18;132(16):1647-1656
pubmed: 30154113
Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e457-e464
pubmed: 31129112
Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1633-42
pubmed: 20428863
Blood. 2008 Sep 15;112(6):2583; author reply 2583-4
pubmed: 18779406
Clin Lymphoma Myeloma. 2008 Jun;8(3):159-65
pubmed: 18650179
J Nucl Med. 2017 Jan;58(1):62-68
pubmed: 27469362
Am J Hematol. 2011 Oct;86(10):841-5
pubmed: 21922524
Bone Marrow Transplant. 2013 Sep;48(9):1212-7
pubmed: 23584442
Am J Hematol. 2017 Aug;92(8):806-813
pubmed: 28699667
Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):565-74
pubmed: 24281821
Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):95-9
pubmed: 17786437
Br J Haematol. 2005 Oct;131(1):29-38
pubmed: 16173960
J Clin Oncol. 2014 Sep 20;32(27):3048-58
pubmed: 25113771
Leuk Lymphoma. 2008 Sep;49(9):1693-701
pubmed: 18798104
Cancer. 2012 Jul 15;118(14):3565-70
pubmed: 22180256
Hematol Oncol. 2019 Feb;37(1):39-46
pubmed: 30299563
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Adv Clin Exp Med. 2015 Mar-Apr;24(2):325-30
pubmed: 25931367
Haematologica. 2020 Jan;105(1):e33-e36
pubmed: 31371411

Auteurs

Domenico Albano (D)

Nuclear Medicine, University of Brescia, Spedali Civili Brescia, 25123 Brescia, Italy.

Riccardo Laudicella (R)

Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, 98125 Messina, Italy.

Paola Ferro (P)

Nuclear Medicine Department, IRCCS San Raffaele Hospital, 20132 Milan, Italy.

Michela Allocca (M)

Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50134 Florence, Italy.

Elisabetta Abenavoli (E)

Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50134 Florence, Italy.

Ambra Buschiazzo (A)

Nuclear Medicine Department, S. Croce e Carle Hospital Cuneo, 12100 Cuneo, Italy.

Alessia Castellino (A)

Hematology Division, S. Croce e Carle Hospital Cuneo, 12100 Cuneo, Italy.

Agostino Chiaravalloti (A)

Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy.
IRCCS Neuromed, 86077 Pozzilli, Italy.

Annarosa Cuccaro (A)

Istituto di Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.

Lea Cuppari (L)

Nuclear Medicine and Molecular Imaging Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.

Rexhep Durmo (R)

Nuclear Medicine, University of Brescia, Spedali Civili Brescia, 25123 Brescia, Italy.

Laura Evangelista (L)

Nuclear Medicine Unit, Department of Medicine - DIMED, University of Padua, 35121 Padua, Italy.

Viviana Frantellizzi (V)

Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.

Sofya Kovalchuk (S)

Hematology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50134 Florence, Italy.

Flavia Linguanti (F)

Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50134 Florence, Italy.

Giulia Santo (G)

Nuclear Medicine Unit, Department of Interdisciplinary Medicine, University of Bari Aldo Moro, 70124 Bari, Italy.

Matteo Bauckneht (M)

Nuclear Medicine, IRCCS Policlinico San Martino, 16132 Genova, Italy.

Salvatore Annunziata (S)

Institute of Nuclear Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.

Classifications MeSH